Overview

Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection

Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
0
Participant gender:
All
Summary
The experiment is divided into two parts: Part 1 and Part 2.Part 1 was the initial treatment patient and Part 2 was the treated patient.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sunshine Lake Pharma Co., Ltd.
Treatments:
Antiviral Agents
Entecavir
Ritonavir
Criteria
Inclusion Criteria:

- Chronic HBV infection population

- HBeAg positive

- HBsAg≥250 IU/mL

- No cirrhosis

Exclusion Criteria:

- AST>5×ULN

- Platelet count less than 90E+09/L

- TBil>1.5×ULN

- albumin<35 g/L

- INR>1.5

- AFP>50 ng/mL